1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy.
(
- Contribution to journal › Article
-
Mark
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours.
(
- Contribution to journal › Article
-
Mark
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
(
- Contribution to journal › Article
- 2014
-
Mark
Molecular and genetic diversity in the metastatic process of melanoma.
(
- Contribution to journal › Article
- 2012
-
Mark
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
(
- Contribution to journal › Article